Production of [89Zr]Oxinate4 and cell radiolabeling for human use

[89Zr]Oxinate4 is a Positron Emission Tomography (PET) tracer for cell radiolabeling that can enable imaging techniques to help better understand cell trafficking in various diseases. Although several groups have synthetized this compound for use in preclinical studies, there is no available data re...

Full description

Saved in:
Bibliographic Details
Published in:Journal of labelled compounds & radiopharmaceuticals 2021-05, Vol.64 (5), p.209-216
Main Authors: Massicano, Adriana V.F., Bartels, Jennifer L., Jeffers, Charlotte D., Crenshaw, Bryant K., Houson, Hailey, Mueller, Christina, Younger, Jarred W., Knapp, Paul, McConathy, Jonathan E., Lapi, Suzanne E.
Format: Article
Language:English
Subjects:
Cell viability
Efflux
Imaging techniques
Leukocytes
Positron emission
Positron emission tomography
Quality control
Radiochemistry
Radiolabelling
radiopharmaceutical
Tomography
Zirconium isotopes
Zr‐89
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[89Zr]Oxinate4 is a Positron Emission Tomography (PET) tracer for cell radiolabeling that can enable imaging techniques to help better understand cell trafficking in various diseases. Although several groups have synthetized this compound for use in preclinical studies, there is no available data regarding the production of [89Zr]Oxinate4 for human use. In this report, we describe the detailed production of [89Zr]Oxinate4 under USP and autologous leukocyte radiolabeling under USP . The final product presented high radiochemical purity and stability at 24 h post synthesis (>99%) and passed in all quality control assays required for clinical use. [89Zr]Oxinate4 did not compromise the white blood cells viability and did not show considerable cellular efflux up to 3 h post labeling. The translation of this technique into human use can provide insight into several disease mechanisms since [89Zr]Oxinate4 has the potential to label any cell subset of interest. In this work, we described the production of [89Zr]Oxinate4 under USP regulations and radiolabeling of autologous leukocyte under USP which make the final product suitable for clinical use.
ISSN:0362-4803
1099-1344
DOI:10.1002/jlcr.3901